Showing results (101-110 of 123) with videos related to

Sort By:
Pageof 13
Journal of Immunology (Baltimore, Md. : 1950)|July 11, 2022
An In Vivo Model of Human Macrophages in Metastatic MelanomaValentin Voillet, Trisha R Berger, Kelly M McKenna, et al.
Plos One|June 6, 2024
qPCR assay for detection of Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Elements from CAR-T and TCR-T cells in fresh and formalin-fixed tissueShalini Pullarkat, Graeme Black, Marie Bleakley, et al.
JCI Insight|August 12, 2024
Expansion of the HSV-2-specific T cell repertoire in skin after immunotherapeutic HSV-2 vaccineEmily S Ford, Alvason Z Li, Kerry J Laing, et al.
Transplantation and Cellular Therapy|May 17, 2026
Expert Panel Review and Practical Guidance on Biomarker Testing With Engineered Immune Effector CellsViktoria Blumenberg, Caroline Diorio, Jordan Gauthier, et al.
The Lancet. Oncology|July 6, 2023
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trialAndrew J Cowan, Margot J Pont, Blythe D Sather, et al.
Haematologica|March 13, 2025
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow upAndrew J Portuguese, Jennifer J Huang, Yein Jeon, et al.
Medrxiv : the Preprint Server for Health Sciences|January 7, 2025
Acute Myeloid Leukemia Skews Therapeutic WT1-specific CD8 TCR-T Cells Towards an NK-like Phenotype that Compromises Function and PersistenceFrancesco Mazziotta, Lauren E Martin, Daniel N Eagan, et al.
Medrxiv : the Preprint Server for Health Sciences|July 15, 2024
Tumor Regression Following Engineered Polyomavirus-Specific T Cell Therapy in Immune Checkpoint Inhibitor-Refractory Merkel Cell CarcinomaYuta Asano, Joshua Veatch, Megan McAfee, et al.
Transplantation and Cellular Therapy|February 28, 2026
Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory HurdlesKedar Kirtane, Michael Kalos, Rocky Billups, et al.
Nature Communications|September 26, 2018
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLAK G Paulson, V Voillet, M S McAfee, et al.
Pageof 13